No takes yet. Share an insight, caveat, or question.
Retrospective study observes sustained declines in breast cancer screening through 2023, indicating ongoing disruption without widening disparities.
Karam et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: